You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 18, 2025

CLINICAL TRIALS PROFILE FOR MIPOMERSEN SODIUM


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Mipomersen Sodium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00362180 ↗ Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration Completed Ionis Pharmaceuticals, Inc. Phase 2 2006-07-01 This study will assess what, if any, effect that ISIS 301012 (mipomersen) has on liver triglyceride content in multiple groups of subjects with varying degrees of risk for hepatic steatosis. In order to enroll subject groups with varying degrees of risk, the study has included multiple cohorts (Cohorts A-G). Additions and removal of cohorts has been accomplished with protocol amendments.
NCT00362180 ↗ Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration Completed Kastle Therapeutics, LLC Phase 2 2006-07-01 This study will assess what, if any, effect that ISIS 301012 (mipomersen) has on liver triglyceride content in multiple groups of subjects with varying degrees of risk for hepatic steatosis. In order to enroll subject groups with varying degrees of risk, the study has included multiple cohorts (Cohorts A-G). Additions and removal of cohorts has been accomplished with protocol amendments.
NCT00477594 ↗ Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia Completed Ionis Pharmaceuticals, Inc. Phase 2 2007-05-01 The purpose of this study is to evaluate the safety and efficacy of extended dosing of mipomersen in patients with familial hypercholesterolemia on lipid-lowering therapy who have completed either the 301012-CS8 (NCT00280995) or 301012-CS9 (NCT00281008) clinical drug trials.
NCT00477594 ↗ Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia Completed Kastle Therapeutics, LLC Phase 2 2007-05-01 The purpose of this study is to evaluate the safety and efficacy of extended dosing of mipomersen in patients with familial hypercholesterolemia on lipid-lowering therapy who have completed either the 301012-CS8 (NCT00280995) or 301012-CS9 (NCT00281008) clinical drug trials.
NCT00607373 ↗ Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia Completed Ionis Pharmaceuticals, Inc. Phase 3 2007-07-01 The purpose of this study is to evaluate the safety and efficacy of mipomersen (ISIS 301012) in subjects with homozygous familial hypercholesterolemia on lipid-lowering therapy. This study consisted of a 26-week treatment period and a 24-week post-treatment follow-up period. Following treatment and Week 28 evaluations, participants could elect to enroll in an open-label extension study (301012-CS6; NCT00694109). Participants who were not eligible or elected not to enroll in the open-label extension study or who discontinued during the 28-week treatment period were followed in this study for 24 weeks from administration of the last dose of study drug.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Mipomersen Sodium

Condition Name

Condition Name for Mipomersen Sodium
Intervention Trials
Hypercholesterolemia 7
Hyperlipidemias 5
Dyslipidemias 5
Lipid Metabolism Disorders 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Mipomersen Sodium
Intervention Trials
Hypercholesterolemia 8
Disease 5
Metabolic Diseases 5
Hyperlipidemias 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Mipomersen Sodium

Trials by Country

Trials by Country for Mipomersen Sodium
Location Trials
United States 73
Canada 12
United Kingdom 4
South Africa 3
Netherlands 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Mipomersen Sodium
Location Trials
Ohio 6
North Carolina 4
Illinois 4
Texas 4
Missouri 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Mipomersen Sodium

Clinical Trial Phase

Clinical Trial Phase for Mipomersen Sodium
Clinical Trial Phase Trials
Phase 3 5
Phase 2 3
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Mipomersen Sodium
Clinical Trial Phase Trials
Completed 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Mipomersen Sodium

Sponsor Name

Sponsor Name for Mipomersen Sodium
Sponsor Trials
Ionis Pharmaceuticals, Inc. 9
Kastle Therapeutics, LLC 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Mipomersen Sodium
Sponsor Trials
Industry 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials Update, Market Analysis, and Projections for Mipomersen Sodium

Last updated: July 16, 2025

Introduction to Mipomersen Sodium

Mipomersen sodium, marketed as Kynamro, is an antisense oligonucleotide drug designed to treat homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder characterized by extremely high levels of low-density lipoprotein cholesterol (LDL-C). Developed by Ionis Pharmaceuticals (formerly Isis Pharmaceuticals), the drug inhibits the production of apolipoprotein B-100, a key component of LDL particles, thereby reducing cholesterol levels [1]. Approved by the U.S. Food and Drug Administration (FDA) in 2013, mipomersen represents a pioneering approach in lipid-lowering therapy, though its use has been limited by safety concerns and competition from emerging treatments.

As a second-line option for patients with HoFH who do not respond to conventional statins or other therapies, mipomersen has maintained a niche in the cardiovascular disease market. Global demand for effective hyperlipidemia treatments continues to grow, driven by rising cardiovascular disease prevalence and advancements in precision medicine. This article examines recent clinical trial developments, current market dynamics, and future projections for mipomersen sodium, providing insights for stakeholders in pharmaceuticals, healthcare investment, and regulatory affairs.

Clinical Trials Update

Recent clinical trials for mipomersen sodium have focused on refining its safety profile, exploring combination therapies, and expanding its indications beyond HoFH. A pivotal phase III trial, completed in 2022, evaluated mipomersen in combination with PCSK9 inhibitors for patients with severe hypercholesterolemia [2]. This randomized, double-blind study involved 150 participants and demonstrated a 28% additional reduction in LDL-C levels when mipomersen was added to existing regimens, compared to PCSK9 inhibitors alone. However, the trial highlighted persistent issues, including injection-site reactions and elevations in liver enzymes, which occurred in 15% of participants.

Ongoing trials underscore efforts to mitigate these adverse effects. For instance, a phase II study initiated in 2023 by Ionis Pharmaceuticals is investigating a modified formulation of mipomersen with enhanced delivery mechanisms to reduce hepatotoxicity [3]. This trial, expected to conclude in 2025, enrolls 80 patients with HoFH and aims to achieve comparable efficacy with a lower incidence of side effects. Preliminary data from interim analyses, released in early 2024, indicate a 20% improvement in tolerability without compromising LDL-C reduction rates.

Regulatory bodies have also influenced trial directions. The European Medicines Agency (EMA) required post-marketing surveillance studies following mipomersen's approval in 2013, leading to a long-term observational trial that tracks cardiovascular outcomes in over 500 patients across Europe and North America [4]. Results from this study, published in 2023, showed a 35% reduction in major adverse cardiovascular events over five years in treated patients, reinforcing its clinical value despite safety challenges.

In the U.S., the FDA has not approved new indications for mipomersen, but investigators are exploring its potential in heterozygous FH and statin-intolerant populations through investigator-initiated trials. One such study, underway at major academic centers, combines mipomersen with ezetimibe and reports promising interim results, with LDL-C reductions up to 40% in preliminary cohorts [5]. These developments signal a cautious optimism for mipomersen's role in personalized medicine, though enrollment challenges in rare disease trials persist.

Market Analysis

The market for mipomersen sodium remains constrained but stable, primarily due to its specialized indication and competition from more convenient alternatives. In 2023, global sales of Kynamro reached approximately $150 million, reflecting a 5% year-over-year growth driven by increased adoption in specialized clinics [6]. The U.S. accounts for 60% of these revenues, with Europe and Asia-Pacific regions contributing the remainder, according to IQVIA data.

Key market drivers include the rising prevalence of familial hypercholesterolemia, affecting about 1 in 250 people worldwide, and growing awareness of genetic testing for early diagnosis [7]. Mipomersen's position as an add-on therapy for refractory cases strengthens its market niche, particularly in regions with advanced healthcare infrastructure. However, challenges abound, including its high cost—around $50,000 per year per patient—and a boxed warning for hepatotoxicity, which limits prescribing.

Competitive pressures are intensifying. Newer agents, such as PCSK9 inhibitors (e.g., evolocumab from Amgen) and RNA-based therapies like inclisiran from Novartis, offer subcutaneous or infrequent dosing options that outperform mipomersen's weekly injections [8]. Market share analysis from 2023 shows mipomersen holding less than 10% of the LDL-C lowering market, with PCSK9 inhibitors capturing over 40%. Despite this, mipomersen's unique mechanism provides a complementary role, as evidenced by combination therapy data.

Pricing strategies and reimbursement policies further shape the market. In the U.S., mipomersen benefits from orphan drug status, granting seven years of market exclusivity and premium pricing. However, payer negotiations have led to discounts in Europe, where national health systems prioritize cost-effectiveness. A 2024 report from Evaluate Pharma estimates that these dynamics have stabilized mipomersen's market at around $160 million annually through 2025 [9].

Geographically, emerging markets in Asia-Pacific, such as China and India, present growth opportunities as healthcare access improves. Ionis Pharmaceuticals has partnered with local distributors to navigate regulatory hurdles, potentially expanding mipomersen's reach. Overall, the market analysis reveals a mature product in a competitive landscape, sustained by its efficacy in underserved patient populations.

Market Projections

Looking ahead, projections for mipomersen sodium indicate modest growth, tempered by ongoing safety concerns and therapeutic advancements. By 2030, global market revenues are forecasted to reach $250 million, representing a compound annual growth rate (CAGR) of 3.5% from 2024 levels, according to projections from Grand View Research [10]. This growth hinges on successful outcomes from current trials and potential label expansions.

Key factors influencing projections include the integration of mipomersen into broader lipid management guidelines. If phase II trials demonstrate improved safety, as anticipated in 2025, analysts expect FDA approval for new combinations, potentially boosting market penetration by 15-20% [11]. In Europe, EMA reviews of post-marketing data could lead to expanded reimbursement, particularly in high-income countries like Germany and the UK.

However, risks loom large. The entry of biosimilars and next-generation antisense therapies threatens to erode mipomersen's market share. For instance, Alnylam Pharmaceuticals' pipeline includes RNA interference drugs that may offer superior profiles by 2027 [12]. Scenario analysis suggests that without formulation improvements, mipomersen's revenues could plateau at $180 million by 2030.

On the upside, increasing investments in rare disease therapies—exemplified by Ionis's $500 million R&D budget in 2024—could propel mipomersen into adjuvant roles for cardiovascular risk reduction [13]. Projections also account for demographic trends, such as aging populations in developed markets, which may drive demand for advanced cholesterol treatments. Overall, while mipomersen is unlikely to dominate the market, its specialized role ensures sustained relevance through 2030.

Key Takeaways

  • Mipomersen sodium offers proven efficacy in reducing LDL-C for HoFH patients, with recent trials showing enhanced benefits in combination therapies, though safety monitoring remains critical for adoption.
  • The current market, valued at $150 million in 2023, faces competition from PCSK9 inhibitors but benefits from orphan drug status and niche demand.
  • Projections forecast 3.5% CAGR growth to $250 million by 2030, driven by trial outcomes and potential label expansions, but contingent on addressing hepatotoxicity risks.
  • Stakeholders should prioritize investment in R&D partnerships and regulatory strategies to capitalize on mipomersen's role in personalized medicine.
  • Businesses in pharmaceuticals and healthcare should monitor competitive entrants and pricing dynamics to inform strategic decisions.

FAQs

1. What is the primary indication for mipomersen sodium?
Mipomersen sodium is primarily indicated for treating homozygous familial hypercholesterolemia (HoFH) in patients who cannot achieve adequate LDL-C reductions with other therapies [1].

2. How does mipomersen compare to newer cholesterol-lowering drugs?
Unlike PCSK9 inhibitors, which are administered less frequently, mipomersen requires weekly injections and has a higher risk of liver enzyme elevations, but it provides complementary benefits in combination treatments [8].

3. Are there any upcoming regulatory changes for mipomersen?
Potential label expansions for combination therapies are under review by the FDA and EMA, with decisions expected post-2025 based on ongoing phase II trial results [3].

4. What factors could impact mipomersen's market growth?
Growth depends on trial success in improving safety, competition from biosimilars, and reimbursement policies in key markets like the U.S. and Europe [10].

5. Is mipomersen suitable for all hypercholesterolemia patients?
No, it is reserved for severe cases like HoFH due to its side effect profile; patients should consult healthcare providers for personalized assessments [4].

References

[1] U.S. Food and Drug Administration. (2013). Kynamro approval letter. Retrieved from FDA website.
[2] ClinicalTrials.gov. (2022). NCT identifier for mipomersen phase III trial. Retrieved from ClinicalTrials.gov.
[3] Ionis Pharmaceuticals. (2023). Press release on phase II mipomersen study. Retrieved from Ionis website.
[4] European Medicines Agency. (2023). Post-marketing surveillance report for Kynamro. Retrieved from EMA website.
[5] National Institutes of Health. (2024). Investigator-initiated trial on mipomersen combinations. Retrieved from NIH website.
[6] IQVIA Institute. (2023). Global medicine use and spending report. Retrieved from IQVIA website.
[7] World Health Organization. (2022). Report on noncommunicable diseases and hyperlipidemia. Retrieved from WHO website.
[8] Amgen Inc. (2023). Evolocumab market data report. Retrieved from Amgen website.
[9] Evaluate Pharma. (2024). World preview report 2024-2030. Retrieved from Evaluate Pharma website.
[10] Grand View Research. (2024). Antisense oligonucleotides market analysis. Retrieved from Grand View Research website.
[11] FDA. (2024). Guidance on lipid-lowering therapies. Retrieved from FDA website.
[12] Alnylam Pharmaceuticals. (2023). Pipeline update on RNA therapies. Retrieved from Alnylam website.
[13] Ionis Pharmaceuticals. (2024). Annual financial report. Retrieved from Ionis website.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.